|Videos|October 13, 2017

What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?

Author(s)Contagion&reg Editorial Staff

Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.

Amanda Paschke, MD, MSCE, director of Clinical Research, Infectious Diseases, at Merck, breaks down the advantages of administering a beta-lactam in combination with a beta-lactamase inhibitor. Dr. Paschke highlights Merck’s development compound imipenem-relebactam, and explains how relebactam restores susceptibility to imipenem.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?

Related Content

From Pathogen to Infectious Disease Diagnosis: Rapid Genotyping Could Bring Ciprofloxacin Back for Gonorrhea Cases

2 Triples and a Dual Regimen Vie for First-Line Against H pylori

From AIDS to COVID-19 to Measles, Why do Infectious Disease Public Health Crises Keep Occurring?

Drawing Borders Around a Borderless Specialty

Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

27th Annual International Lung Cancer Congress®

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Tennessee Oncology Practice Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Colorado Oncology Society

IgAN Case Files: Real Conversations, Evolving Evidence

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

From Gene to Gut: Understanding TL1A’s Function in IBD Evolution

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Medical Crossfire®: Experts Debate the Hottest Topics in AML – FLT3, IDH1/2, KMT2Ar, NPM1, Secondary AML, Maintenance, Novel Combinations, and Emerging Therapies

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Kentucky

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

2026 Carolina Neuromuscular Disease Summit

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Nevada Oncology Society

Kansas Society of Clinical Oncology

EyeCon 2026

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Rhode Island Oncology Society

Satellite Symposia at the Annual Radiation Oncology Meeting

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Washington State Medical Oncology Society

The Optometry Meeting in Anaheim

North Carolina Oncology Association

Jersey City Psychiatry

Join Us at The Pathology Meeting in Las Vegas

Join Us at The Pathology Meeting in Las Vegas

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Montana/Wyoming

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Indiana Oncology Society

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Nevada Oncology Society

Louisiana Oncology Society

Wyoming State Oncology Society

Montana State Oncology Society

Precision in Practice: Advancing Prostate Cancer Care With PSMA-Directed Radioligand Therapy

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

ISGIO 2025: Advanced-Stage Colorectal Cancer

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate